Citation Impact
Citing Papers
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy
2011
Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors
2009 StandoutNobel
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
2003 StandoutNobel
In vivo Effects of Vaccination with Six-Transmembrane Epithelial Antigen of the Prostate: A Candidate Antigen for Treating Prostate Cancer
2007
Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy
2011 StandoutNobel
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
2013 StandoutNobel
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
2009 StandoutNobel
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
2008 StandoutScienceNobel
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
2013 StandoutNobel
Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment
2011
Targeted cell killing by reconstituted caspases
2007 StandoutNobel
Aire-Dependent Thymic Development of Tumor-Associated Regulatory T Cells
2013 StandoutScienceNobel
Androgen-independent prostate cancer progression in the TRAMP model.
1997
Defects in the Acquisition of CD8 T Cell Effector Function after Priming with Tumor or Soluble Antigen Can Be Overcome by the Addition of an OX40 Agonist
2007
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
2019
Reduced maternal expression of adrenomedullin disrupts fertility, placentation, and fetal growth in mice
2006 StandoutNobel
Stromal fibroblasts in cancer initiation and progression
2004 StandoutNature
Therapeutic activity of 3,3′‐diindolylmethane on prostate cancer in an in vivo model
2004
Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion
2005 Standout
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
2017 StandoutNobel
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer
2006
Lymphangiogenesis: Molecular Mechanisms and Future Promise
2010 Standout
CTLA-4: new insights into its biological function and use in tumor immunotherapy
2002 StandoutNobel
Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model
2003
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Myeloid Cells Contribute to Tumor Lymphangiogenesis
2009
Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens
2010
Role of the stromal microenvironment in carcinogenesis of the prostate
2003
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
2011 StandoutNobel
Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer
2012 StandoutNobel
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
Receptor Activity-modifying Proteins 2 and 3 Have Distinct Physiological Functions from Embryogenesis to Old Age
2007 StandoutNobel
Biomarkers in Heart Failure
2008 Standout
Hypertonic Induction of Aquaporin-5 Expression through an ERK-dependent Pathway
2000 StandoutNobel
Hemodynamic, Renal, and Hormonal Effects of Adrenomedullin Infusion in Patients With Congestive Heart Failure
2000
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
2008 StandoutNobel
Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer.
2001
Bis- and Trisindolylmethanes (BIMs and TIMs)
2009 Standout
Adrenomedullin gene expression differences in mice do not affect blood pressure but modulate hypertension-induced pathology in males
2007 StandoutNobel
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
2014 StandoutNobel
Hydrops Fetalis, Cardiovascular Defects, and Embryonic Lethality in Mice Lacking the Calcitonin Receptor-Like Receptor Gene
2006 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine
2001 StandoutNobel
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
2008 StandoutNobel
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model
2012 StandoutNobel
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
The TRAMP Mouse as a Model for Prostate Cancer
2001 StandoutNobel
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.
2000 StandoutNobel
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice.
2001
Zinc-sensitive MRI contrast agent detects differential release of Zn(II) ions from the healthy vs. malignant mouse prostate
2016
Role of Endogenous Adrenomedullin in the Regulation of Vascular Tone and Ischemic Renal Injury
2002
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Tonicity-responsive enhancer binding protein, a Rel-like protein that stimulates transcription in response to hypertonicity
1999
CD4 cells can be more efficient at tumor rejection than CD8 cells
2007
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy
2001 StandoutNobel
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
2013 StandoutNobel
Adrenomedullin: Potential in physiology and pathophysiology
2000
Pathologic progression of autochthonous prostate cancer in the TRAMP model
1999
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy
1999 StandoutNobel
Works of E.D. Kwon being referenced
Betaine and inositol reduce MDCK cell glycerophosphocholine by stimulating its degradation
1996
Osmoregulation of GPC:choline phosphodiesterase in MDCK cells: different effects of urea and NaCl
1995
Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
1997